logo
  

Ionis: AstraZeneca Decides Not To Advance ION449 Into Phase 3 Based On Pre-specified Criteria

Ionis Pharmaceuticals, Inc. (IONS) said topline results from the phase 2bSOLANO study in patients with hypercholesterolemia showed that 60mg of ION449 administered monthly achieved a statistically significant 62.3% reduction in low-density lipoprotein cholesterol levels after 28 weeks compared to placebo, meeting the study's primary efficacy endpoint. However, the results did not achieve pre-specified efficacy criteria and AstraZeneca has decided not to advance ION449 into phase 3 development for hypercholesterolemia.

"While the LDL-C reductions seen in high-risk hypercholesterolemia patients on maximum statin therapy were both statistically significant and robust, these results did not meet AstraZeneca's target product profile criteria to invest in a broad phase 3 development program," said Eugene Schneider, chief clinical development officer at Ionis.

For More Such Health News, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Stocks staged a significant recovery attempt after pulling back sharply in early trading on Wednesday but still ended the day modestly lower. The major averages gave back ground after moving sharply higher over the two previous sessions. Three scientists have shared the Nobel Prize for Chemistry for their work that led to the development of linking molecules together, known as click chemistry, and bioorthogonal chemistry. Morten Meldal and K. Barry Sharpless have laid the foundation for a functional form of chemistry - click chemistry - in which molecular building blocks snap together quickly and efficiently. Carolyn R. Bertozzi The Institute for Supply Management released a report on Wednesday showing a modest slowdown in the pace of growth in U.S. service sector activity in the month of September. The ISM said its services PMI edged down to 56.7 in September from 56.9 in August, although a reading above 50 still indicates growth in the sector.
Follow RTT